High Intensity Interval Training or Strength Training in Women With Polycystic Ovary Syndrome

Not Applicable

Completed

• Conditions: Polycystic Ovary Syndrome

• Registration Number: NCT01919281
• Lead Sponsor: Norwegian University of Science and Technology

Brief Summary

The aim is to investigate whether strength training or high intensity interval training is effective in improving insulin sensitivity, cardiovascular outcomes, body composition and reproductive outcomes in women with Polycystic Ovary Syndrome (PCOS).

Few studies have examined the effect of strength training alone on insulin sensitivity, reproductive outcomes and body composition in women with PCOS. Most previous studies on aerobic exercise in PCOS have applied moderate exercise intensity.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-07
• Study First Submitted: 2013-07-17
• Study First Submitted QC: 2013-08-06
• Study First Posted: 2013-08-08
• Primary Completion: 2014-01
• Study Completion: 2015-04
• Status Verified: 2015-05
• Last Update Submitted: 2015-09-28
• Last Update Posted: 2015-09-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 31

Inclusion Criteria

• Women
• Age 18-45 years old
• PCOS

Exclusion Criteria

• Regular high intensity endurance or strength training (two or more times per week of vigorous exercise).
• Concurrent treatments (insulin sensitizers or drugs known to affect gonadotropin or ovulation, with a wash out period of 1 months prior to inclusion).
• On-going pregnancy.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
insulin resistance	10 weeks	measured with the homeostatic model assessment for insulin resistance (HOMA-IR) method

Secondary Outcome Measures

Name	Time	Method
Body composition	10 weeks	Measured as body fat % on an impedance scale and waist circumference
Maximum oxygen uptake	10 weeks	Measured during maximum effort exercise test
Endothelial function	10 weeks	Flow mediated dilatation of the brachial artery.

Trial Locations

Locations (1)

Department of circulation and medical imaging , NTNU; 🇳🇴 Trondheim, Norway